ieumBio has been selected for the 2026 H2 IBK Changgong Acceleration Program, one of Korea's leading acceleration programs for innovative technology startups.

The program supports promising companies through business acceleration, strategic mentoring, industry networking, and commercialization support, helping them scale innovative technologies into global markets.

For ieumBio, this selection represents another important milestone in the commercialization of KilliSpan™, our rapid vertebrate longevity evaluation platform. Through the program, we will continue expanding partnerships with pharmaceutical companies, biotechnology innovators, research institutions, and investors while strengthening our global business capabilities.

Following our recent selection for Tech Launch 2026 PhaseⅡ and the BNK CHAIN-G Program, this achievement further reinforces ieumBio's long-term vision of establishing the global standard for longevity evaluation.